Our Parliamentary Affairs and Policy and Evidence teams have submitted their calls to the Government as part of the feedback process for the Spending Review.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Once opened, compounded semaglutide typically lasts 28 days in the fridge. Compounded semaglutide, which contains the same active ...

Rybelsus (semaglutide) is a brand-name oral tablet prescribed for type 2 diabetes. As with other drugs, Rybelsus can cause side effects, such as nausea, vomiting, and constipation. Read on to ...

Polymer Chemistry Communications contain novel scientific work of such importance that rapid publication is desirable. Authors should briefly indicate in a covering letter the reasons why they feel ...

"Millions of Part D patients who rely on price-controlled drugs will see their out-of-pocket ... [+] medication costs increase," writes Pipes. Just three days before President Biden left office ...

Learn More » On Friday morning, Novo Nordisk unveiled the latest results from a clinical trial of CagriSema, an investigational drug leveraging the foundational semaglutide molecule used in Wegovy.

The key is the ligand — that’s the general word for whatever chemical messenger or signaling ... Ozempic, or semaglutide, is a GLP-1 agonist, meaning its molecules mimic the structure of GLP-1, ...